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Abstract 
Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global 
healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular 
carcinoma. Although current treatment strategies, Interferon and nucleos(t)ide analogues have 
contributed to reducing morbidity and mortality related to CHB, these therapies are limited in 
providing functional cure. The treatment paradigm in CHB is rapidly evolving with a number of new 
agents in the developmental pipeline. However, until novel agents with functional cure capability are 
available in the clinical setting, there is a pressing need to optimise currently licensed therapies.  
Here we discuss current agents used alone and/or in combination strategies along with the impact of 
these therapies on viral and immune responses. Novel treatment strategies are outlined and the 
potential role of current therapies in the employment of pipeline agents is discussed.   
 
 
KEYWORDS: Hepatitis B surface antigen; Nucleos(t)ide analogues; Pegylated Interferon; T cells, NK 
cells 
 
Introduction 
The introduction of a preventative vaccine for Hepatitis B virus (HBV) has led to the overall reduction 
in the incidence of chronic infection. This unfortunately is not the case for many middle and low 
income countries, thus chronic hepatitis B (CHB) remains a major global healthcare challenge. In line 
with this, the viral hepatitides are the only communicable disease whereby there has been an 
increase in related morbidity and mortality over the last 20 years1. Both HBV and hepatitis C virus 
(HCV), contribute to end-stage liver disease and hepatocellular carcinoma (HCC). HCV remains 
prevalent in North America and Europe, although novel direct-acting antivirals (DAAs) now provide 
cure rates of >90% for chronic HCV2. CHB remains prevalent in Asia and sub-Saharan Africa1, but 
recent migration patterns have lead to an increase in the prevalence of CHB in the western world3. 
An estimated 250 million people are chronically infected, hepatitis B surface antigen (HBsAg) 
seroprevalence is approximately 4% globally, with much higher prevalence in Africa approaching 
10% and 5% in the Western Pacific4,5. HBV is transmitted haematogenously and sexually; in high 
prevalence regions, the majority of HBV infections are transmitted vertically (or perinatally) 6. 
 
HBV infection acquired at birth or in early childhood, will result in chronicity in >95% of subjects. On 
the contrary, only 5-10% of those who acquire the virus in adulthood will progress to chronic 
infection. Despite the use of passive-active immunoprophylaxis with HBV immunoglobulin and HBV 
vaccine, babies born to highly viraemic mothers are at risk of acquiring the infection. However, the 
risk of vertical or perinatal transmission can be significantly reduced by the administration of 
antiviral therapy to highly viraemic Hepatitis B envelope Antigen (HBeAg) positive mothers in the last 
trimester of pregnancy, which is in line with current national and international treatment guidelines 
7-9. Given the rise in UK prevalence of HBV, secondary to migration from endemic areas, hepatitis B 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
has now been added to the infant vaccination schedule10. It is predicted that the incidence of HBV-
related HCC will increase in the coming years11 and thus it is vital for investment into new HBV 
therapeutics to prevent the complications of chronic infection and HCC.  
 
Previous national and international guidelines suggested that HBeAg positive patients in the immune 
active (HBeAg positive chronic hepatitis; raised ALT with HBV DNA) or those in the HBeAg negative 
immune escape phase (HBeAg negative chronic hepatitis; raised ALT and/or HBV DNA) are deemed 
treatment candidates.  More recent guidelines have lowered the threshold for treatment candidacy 
to HBV DNA levels >2,000 IU/ml 12-14. Despite evidence that high viral load, regardless of liver 
inflammation correlates with HCC15, those patients previously considered immune tolerant (HBeAg 
positive chronic infection) are excluded from therapy16. Recent data have challenged the concept of 
immune tolerant disease17,18, providing weight to the argument for earlier treatment in young CHB 
patients 19, where blocking viral replication and reducing oncogenic progression in earlier stages of 
CHB may be a more effective strategy. When treatment is withheld until there is elevation in serum 
ALT or until HBeAg seroconversion occurs, it is likely that patients will already experience significant 
cumulative hepatocyte turnover and be at increased risk of clonal hepatocyte expansion20. The 
recent European Association for The Study of the Liver international guidelines (EASL 2017) 
proposed new nomenclature for disease phase in CHB with potential implications for the early 
treatment of patients12. The timing of treatment initiation in patients is discussed in detail 
elsewhere16,21. 
 
With novel CHB therapies in the developmental pipeline, the potential to increase the treatment 
candidacy pool also exists. Although existing therapies are limited in providing a functional cure, 
defined as HBsAg loss, they may still be employed in combination or sequential therapy strategies, 
whilst new drugs are in early phase clinical trials. Currently licensed therapies are discussed here 
along with their impact on the immune response in conjunction with modifications in viral response. 
In addition, we briefly outline novel pipeline therapies and how existing therapies may retain a role 
in combination approaches with new therapies in the future. 
 
Treatment paradigm in HBV  
Therapy options with curative intent for CHB are unlikely to be available for several years, thus 
patients with chronic infection remain at risk of developing liver cirrhosis and HCC. Current 
treatments for HBV include Pegylated Interferon (Peg-IFNα) and Nucleos(t)ide analogues (NAs), but 
neither are efficient in delivering functional cure22.  
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Interferon 
Conventional interferons (IFN) (Intron A) were first licensed in 1991 for use in the treatment of CHB. 
In 2005, a pegylated interferon (Peg-IFNα; Pegasys) version, with the attachment of polyethylene 
glycol, replaced standard IFN due to improved pharmacokinetic properties, providing continuous 
drug exposure over the entire dosing interval, thus offering a less demanding injection schedule with 
comparable efficacy23. IFN provides a dual mode of action; antiviral via inhibition of viral replication, 
and immunomodulatory via enhancement of the host immune response against the virus. Peg-
IFNα’s direct antiviral activity induces epigenetic modifications in the histones binding cccDNA 
causing an accelerated decay of replication-competent HBV nucleocapsids24. These direct antiviral 
effects, however, have limited potency in HBV infection. This is confirmed by the slow kinetic of HBV 
DNA inhibition observed in IFNα treated CHB patients, in comparison with the sharp decline of HCV 
RNA observed in patients with chronic HCV infection25. The ability of IFNα therapy to suppress HBV 
replication is more likely associated with its immunomodulatory effects26,27. 
 
Peg-IFNα therapy offers a finite treatment course, is primarily more effective in those of younger 
age, with moderate viraemia and has the advantage of no antiviral resistance. Its overall success is 
limited to a small proportion of patients; approximately 10% of those treated achieve functional 
cure, defined as sustained serum aviraemia and loss of HBsAg. However, approximately 30% of 
HBeAg-positive patients have a favourable response to Peg-IFNα with sustained HBeAg 
seroconversion with a proportion of these patients going on to achieve HBsAg loss28. Importantly, 
Peg-IFNα also has a role in HBeAg-negative disease, where a sustained virologic response (HBV DNA 
<2000 IU/ml) is seen in up to 40% of patients and HBsAg loss reported in approximately 12% at 5 
years post-treatment29. The use of ‘early stopping rules’ based primarily on HBsAg decline at week 
12 (or 24) of therapy can guide physicians in determining a sub-optimal response; thus avoiding the 
potential undesirable systemic effects associated with a full treatment course. This strategy would 
allow an early switch to NA therapy, providing an individualised approach to CHB treatment28-30.  
 
 
Nucleos(t)ide analogues 
NAs sufficiently suppress the production of new virions, reducing HBV DNA to undetectable levels in 
the serum and normalising transaminases, but HBsAg loss is rarely achieved31. Lamivudine (LAM) was 
the first nucleoside analogue approved for use in 1998 and although it has now been replaced by 
agents with higher genetic barriers to resistance, it played a major role in the transition of CHB 
management allowing dramatic reductions of HBV DNA with the potential to improve disease 
outcomes32. In 2002 Adefovir (ADV), the first nucleotide analogue was licensed, however, although it 
had adequate viral potency, this was outweighed by problems associated with resistance and renal 
toxicity33. Entecavir (ETV) was introduced in 2005 as a potent inhibitor of HBV polymerase and still 
has a role in the HBV treatment arena today. Generally, it has a high genetic barrier to resistance, 
which is decreased in patients with previous LAM resistance. Another nucleoside analogue, 
Telbivudine (LdT) was introduced in 2006 and although this agent was efficacious in reducing HBV 
DNA and having a role in the prevention of mother-to-child-transmission, it is no longer 
recommended as first-line therapy, due to viral resistance and its side-effect profile34. In 2008 
Tenofovir Disporoxil Fumarate (TDF) was approved for use in CHB. It is structurally similar to ADV, 
but has excellent durability of response. Thus, older agents such as LAM and ADV have now been 
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superseded by TDF and ETV (3rd generation NAs) (Figure 1), characterised by  a high genetic barrier 
to resistance, these drugs now represent  first-line therapy or are employed following sub-optimal 
response to Peg-IFNα30. 
 
Recent studies have demonstrated histological improvement (reversal of fibrosis) and reduced 
development of cirrhosis with long-term NAs35. Importantly there may also be a reduction in HCC 
development, but this needs to be substantiated in large clinical trials36. The REVEAL study 
demonstrated elevated HBV DNA to be strongly associated with cirrhosis and the development of 
HCC and thus NAs may have an impact on limiting disease progression37. NAs directly target HBV 
DNA synthesis and are ineffective in their ability to eradicate the cccDNA, the episomal form of HBV 
from infected cells31. Treatment with NAs is considered long-term with limited data on treatment 
discontinuation, which results in reactivation of HBV in the majority31. Recent data, however, 
demonstrates that certain patient cohorts may be able to stop NA therapy, with declines in HBsAg 
38,39 and immune markers to identify such patients are emerging40. Although the side-effect profile of 
3rd generation NAs is favourable, potential drug toxicity with long-term use of TDF may occur, with a 
negative impact on bone mineral density41. For this reason, newer agents namely Tenofovir 
Alfenamide (TAF), although equally efficacious as 3rd generation TDF, has been shown to have a 
more favourable side-effect profile42. 
 
Viral and Immune aspects of therapy 
The drug development pipeline in HBV is rapidly advancing and thus we are on the cusp of major 
change in the treatment of CHB. It is likely that many of these strategies may require combination 
therapy with NAs and/or Peg-IFNα, and therefore current therapies may constitute a central 
component of any future treatment regimen43. In this regard, the optimisation of currently licensed 
therapies still remains important. Both NAs and Peg-IFNα have shown some ability to restore 
immune function in CHB. A number of studies, albeit limited, have investigated the role of current 
therapies on viral and immune responses, to determine if these can be harnessed to deliver better 
treatment outcomes. 
 
Interferon 
Peg-IFNα can offer sustained immune control in a proportion of CHB patients, lead to HBsAg loss and 
seroconversion at higher rates than that seen with NAs. IFN is an innate immune cytokine; it induces 
ISG’s encoding antiviral proteins and activates immune cells. A recent study from the woodchuck 
model showed the induction of a T/NK cell signature in the liver correlating with treatment outcome, 
highlighting that it may have a more predominant role in immune modulation, rather than an 
antiviral mechanism44. Although the decline in HBV DNA may be slow with Peg-IFNα, circulating virus 
decreases as does HBsAg in a cohort of patients. These markers, however, may not be ideal 
surrogates for the viral kinetics of the intrahepatic compartment. More recently, hepatitis B core 
related antigen (HBcrAg), which can be measured in the blood has been proposed as a more 
accurate surrogate of the intrahepatic milieu (cccDNA and intrahepatic viral replication) than HBsAg. 
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HBcrAg was recently demonstrated to reflect cccDNA in HBeAg negative disease and thus may be a 
better determinant of the viral dynamics in patients treated with Peg-IFNα. In line with this, hepatitis 
B-core antibody levels have also been shown to correlate with HBV DNA and HBsAg seroclearance45. 
In addition, HBV RNA can also be measured in the serum and levels are thought to reflect 
intrahepatic cccDNA46. Validation of these markers along with their correlation with immune 
responses in patients treated with Peg-IFNα, or other novel immune modulators, requires further 
study. 
 
IFN is known to activate the innate immune response. Micco et al., demonstrated with a 48-week 
course of Peg-IFNα that there was potent expansion of activated (HLA-DR+, Ki67+ and TRAIL+) 
CD56bright NK cells and recovery of their antiviral potential, (IFNγ production), in HBeAg negative 
disease,26 findings subsequently confirmed in a HBeAg positive cohort27. Peg-IFNα, following 
administration, induces a rapid upregulation of the IFN signalling pathway, as marked by increases in 
serum cytokines, IL-16, IL-6, CXCL10. Therapy with Peg-IFNα alone, however, does not result in a 
rapid decline of viral load, thus highlighting its predominant immune modulatory action47. In a recent 
study, patients treated with IFN; NKp30+ NK cells were found to be associated with HBV control, 
with IL-15 contributing to the upregulation of functional antiviral NK cells. Interestingly, in non-
responders to IFN, NKp30+ NK cells were found to be dysfunctional with an expansion of the 
inhibitory receptor NKG2A48. In the same cohort of patients, an expansion of CD3brightCD56+ T cells 
(innate-like T cells) expressing high levels of NKG2A and low CD8 were associated with non-response 
to IFN. These non-responders had increased levels of TIM3+ CD3brightCD56+ T cells, which negatively 
correlated with IFNγ production contributing to the dysfunction of these cells and potentially 
contributing to poor responses to IFN49. Further evaluation of innate-like T cell populations, such as 
MAIT cells, during IFN therapy is required to determine if their function can be recovered by reduced 
expression of inhibitory molecules PD-1 and CTLA-4, which contribute to the dysfunctional immune 
response in CHB50. KIR genotyping has also been studied where the combination of genes encoding 
KIR3DS1 and HLA-B Bw4-80Ile synergistically predicted sustained responders to Peg-IFNα51. Toll-like-
receptors (TLRs) have been studied in Peg-IFNα treated patients where a favourable response is 
associated with elevated levels of TLR2 and TLR2 associated IL-6 production at baseline, indicating 
that an inflammatory phenotype is more likely to be associated with a favourable treatment 
response52. Such markers and genotyping might facilitate patient selection for treatment with Peg-
IFNα, which would be relatively simple to undertake. 
 
Although only proven in small studies, IFNα therapy may have a more negative effect on HBV-
specific adaptive immunity. Despite the fact that the cytokine can increase T cell survival, boost viral 
antigen presentation and trigger IL-12 production, which might directly rescue the function of 
exhausted T cells53, HBV-specific T cell responses in treated patients are inhibited by Peg-IFNα 
therapy26,54. A recovery of HBV-specific T cell function is only observed after Peg-IFNα therapy 
cessation in treatment responders55 and these patients also exhibit increased HBV-specific T-helper 
cell proliferation 56. Of note, the expression of inhibitory check-point markers (PD-1, Lag-3 and CTLA-
4) does not change on T cells during Peg-IFNα therapy26,47. Peg-IFNα leads to an expansion of IL-10 
producing T-regs in non-responders, which may contribute to HBV persistence. In addition, γδ T cells 
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have been shown to decrease during Peg-IFNα treatment, although the effector phenotype (CD27-
CD45RA+) and production of cytokines from these cells is enhanced in patients with sustained 
response, but not in non-responders57. The negative effects of IFNα on virus-specific T cell responses 
have been detected in studies of LCMV infected mice, where T cell responses were restored by 
inhibiting the effects of virus-induced IFNα rather than by treating the infection with it58,59. As NK 
cells can negatively regulate HBV-specific T cells, the mechanisms of HBV-specific T cell inhibition 
during IFNα therapy might be mediated by NK cells60. However, this is controversial since recent 
studies in animal models demonstrated that type-I IFN may protect T cells from NK cell mediated 
attack61,62 and thus merits further investigation. As Peg-IFNα and NAs act differentially on the 
immune response, the rationale for re-evaluating combination or sequential treatment is required 
for future therapeutic approaches, which are discussed further here.  
 
Nucleos(t)ide analogues 
The 3rd generation NAs have excellent rates of viral suppression, but have little impact on HBsAg 
levels. Detailed evaluation of the intrahepatic viral repertoire during NA therapy is limited. Studies 
have shown that serum HBV DNA correlates with intrahepatic HBV DNA mainly in treatment naïve 
patients, but this is less clear in patients undergoing NA therapy. For example, after many years of 
therapy, serum HBV DNA may be undetectable, but the intracellular/intrahepatic viral HBV DNA only 
appears to reduce by 1-2 logs63. Thus, a lack of serum viraemia does not reflect the intrahepatic viral 
DNA. The decline in HBsAg levels during NA therapy is slow, and any correlation between HBsAg and 
cccDNA is unlikely to be statistically significant as the regulation of HBsAg expression is complex. It is 
now recognised that factors other than the quantity of cccDNA in infected hepatocytes, its 
transcriptional regulation, and the possibility that envelope proteins could be expressed from viral 
sequences integrated into the host genome also contribute to HBsAg levels64. As HBcrAg may 
correlate with serum HBV DNA and intrahepatic cccDNA65,as shown in patients treated with NA with 
a decline in intrahepatic cccDNA, it is possible that HBcrAg may better reflect the intrahepatic 
compartment than HBsAg66. 
 
The rapid decline of HBV DNA secondary to NAs, and the inhibition of HBV DNA polymerase 
function, may allow for the restoration of IFN signalling, however, the data to support this are 
lacking. The increment of ISGs has only been demonstrated in the peripheral compartment of HBeAg 
positive patients treated with TDF47. The effect of NAs on T cell responses has shown a recovery of 
CD4 and CD8 T cell function67-71. During the initial phases of NA treatment CD4 T cell responses are 
stronger than those from CD8 T cells, and the presence of new and expanded clonotypes inversely 
associate with the decline of viral antigen, demonstrating that a broad T cell expansion is critical in 
HBeAg control72. It is important to note that following NA administration, T-cell recovery is often 
partial and not uniform in all treated subjects69. The functional recovery of antiviral immunity is 
likely to be dependent on the ability of NAs to reduce liver inflammation, marked by a reduction in 
serum transaminase levels. These events are linked with the reduction of a number of 
immunological suppressive factors (e.g. IL-10, arginase and T-reg frequencies)73, impacting T cell 
recovery. Importantly studies have demonstrated a restoration of the balance of Th17/T-regs with 
reductions of IL-10 and TGF-β upon viral suppression74,75. 
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In addition to a robust HBV-specific T cell response, critical in eliminating HBV infected hepatocytes, 
NK cells have also shown importance in HBV pathogenesis. A number of studies describe NK cell 
dysfunction in CHB patients, compared with healthy controls27,76,77. NA monotherapy does not 
appear to restore antiviral NK cell function and further adjunct therapy is likely required for this 
innate boosting27,76. Such findings have also been confirmed in the intrahepatic compartment, where 
viral suppression resulted in limited changes in NK cell function78. However, during early NA 
treatment, in patients with raised transaminases, LdT demonstrated an expansion of CD56bright NK 
cells via upregulation of IL-15 and NKG2D, which may be important in viral control79, however, larger 
studies are required to evaluate NK cell phenotype and function along with KIR genotyping. NAs 
have been shown to improve T cell function, although the data regarding non-conventional T cells is 
sparse. One study reported on the presence of activated MAIT cells in CHB, with functional recovery 
upon viral suppression80. With regards to antigen specific adaptive immune responses, Boni et al., 
reported on the recovery of HBV-specific T cells, following expansion, in patients on long-term NA 
therapy, revealing that T cell function may be improved with HBV DNA suppression. This recovery is 
more pronounced in those who clear HBsAg during NA therapy. Regardless, these data reveal that T 
cell function may be improved with reduction of viral load69. This reduction of viraemia by NAs 
provides an ideal window for reconstitution of the antigen specific immune response, which may be 
important in future therapeutic strategies for HBV.  
 
Antigen specific T cell recovery, albeit partial, is possible with NAs, but the impact on antiviral NK 
function is still inferior76. In HBV, the role of NK cells has generated some controversy; described as a 
‘double edged sword’, whether they provide a pathogenic or protective role continues to be 
debated60. A robust antiviral NK cell response is important for cytolysis of HBV infected 
hepatocytes81, however, NK cells also have a regulatory role, causing deletion of HBV-specific T cells 
when in close contact82. The interaction of TRAIL+ and NKG2D+ NK cells with T cells expressing the 
receptor, TRAIL-R2 and/or NKG2D ligands leads to T cell apoptosis, which, in vitro, can be partially 
prevented by blockade of these pathways82,83. The data on whether the phenotype of NK cells is 
altered, with viral load reduction, are limited. A recent report demonstrated an inverse correlation 
with an ‘activatory’ NK cell phenotype (HLA-DR+, CD38+, Ki67+, TRAIL+, NKG2D+) and the proportion 
of HBV-specific T cells in patients undergoing NA therapy84. The regulatory role of NK cells and the 
interaction with T cells, may of course be a protective homeostatic mechanism for the liver 
microenvironment, where NK cells govern T cell mediated immune pathology. However, in an 
attempt to curb liver damage by down-regulating bystander T cells, HBV-specific T cells are also 
dampened. These concepts, however, require further elucidation, ideally with focused ‘on-
treatment’ studies of the liver compartment and to determine the impact of therapy on tissue-
resident immunity 85-88.  
 
Combination/sequential/add-on therapies 
With their differential action on the immune response; NAs and Peg-IFNα used in combination, ‘add-
on’ or sequentially may generate additive or synergistic effects and could be important in future 
therapeutic strategies. Recent clinical studies have shown the combination or addition of Peg-IFNα 
to NAs results in greater HBeAg seroconversion rates in HBeAg positive patients along with greater 
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declines and loss of HBsAg89-91. Thus their use in the clinical setting requires further consideration, 
while the outcomes of such studies performed to date, have been extensively reviewed elsewhere92. 
 
Addition of Peg-IFNα, in a cohort of patients virally suppressed on NAs, induced the activation of 
DC’s, expansion of CD56bright NK cells and increased the frequency of Th1/Th17-orientated HBV-
specific T cells93. Notably, these effects were not associated with improved clinical outcomes. Viral 
load reduction is able to maintain the immune stimulatory effects of Peg-IFNα, when administered in 
combination or sequence, compared to Peg-IFNα alone, which implies there may be beneficial 
outcomes with add-on or combination therapies47. This has been further demonstrated where Peg-
IFNα add-on was employed in patients virally suppressed with ETV, resulting in a reduction in T-reg 
frequencies with an increase in NKG2C+ NK cells and TLR-2+ CD14 monocytes, which was associated 
with treatment response94. In the same cohort the expansion of CD56bright NK cells expressing 
activatory receptors NKp30 and NKp46 along with TRAIL and IFNγ correlated with HBsAg decline 
with potential cccDNA clearance through TRAIL induced cytolysis, demonstrating the importance of 
Peg-IFNα for immune modulation and HBV clearance95. Similarly, in patients primed with Peg-IFNα 
prior to viral suppression the maintenance of expanded functional CD56bright NK cells has been shown 
to correlate with treatment response27. It is noteworthy that the recovery of non-conventional T 
cells (iNKT and γδ T) was limited despite significant declines in HBsAg in a cohort of patients 
undergoing combination therapy96.  
 
In a study of combination Peg-IFNα with ADV, those patients achieving HBsAg loss demonstrated 
increased frequency of TRAIL+, IFNγ+ NK cells at the end of treatment. This indicates that NK cells 
may play a role in the clearance of HBsAg with this therapeutic approach97. In the same patients with 
HBsAg loss, T cells, with broad antiviral capacity could be expanded98. Interestingly, in this study, 
baseline levels of HBsAg/anti-HBs immune complexes were higher in patients that went on to lose 
HBsAg, which may also be a factor in selecting patients for such combination therapy approaches99. 
Peg-IFNα add-on therapy has also been shown to increase TNFα-monofunctional HBV-S and core-
specific CD4 T cell numbers, which may contribute to viral control100. Along with the direct analysis 
of immune cells microRNAs (miRNA) have been reported to be regulated in liver disease. miRNA-155 
is a key regulator of innate and adaptive immunity and the higher expression of miRNA-155 at 
baseline was associated with improved treatment response and NK cell function101. Further studies 
of miRNA’s and their role in HBV and the immune response is warranted and important in future 
therapeutic strategies. The type-III interferon Peg-IFNλ, in combination with NA therapy has also 
been shown to induce robust innate and adaptive immune responses, where NK cell 
polyfunctionality along with recovery of HBV-specific T cells was observed in patients with enhanced 
HBV DNA and HBsAg decline102. This highlights the importance of immune modulation with viral 
suppression as key elements for HBV therapy. 
 
The schedule of therapies remains crucial and this may need revisiting to optimise patients for 
future trials, especially if the treatment pool is widened. The concept of combination or IFN based 
therapies still needs further investigation in larger studies with parallel analysis of both the innate 
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and adaptive immune response. Adjusting the sequence in which therapies are combined is 
potentially important in altering treatment outcome, but may also prime patients for future clinical 
trials, which is a key avenue of exploration.  
 
Novel pipeline therapies for HBV  
Multiple therapeutic approaches for HBV, targeting steps of HBV replication and restoring the host 
immune response are in development. Even with the advent of new therapies, currently licensed 
therapies are likely to remain a backbone of HBV management in the short to medium term, 
especially the employment of NAs for viral suppression. Novel drug targets are entering clinical trials 
to determine efficacy and are discussed at length elsewhere103-106. Here, we outline a selection of 
novel agents and their potential role in combination with currently licensed therapies. 
 
Viral Targets 
The identification of the cellular receptor for HBV entry, NTCP, along with an improved 
understanding of cccDNA formation, degradation and its epigenetic control and targets for viral 
entry have provided significant impetus to the field.  The entry inhibitor Myrcludex B, has shown 
promise in pre-clinical trials of HBV and hepatitis delta virus (HDV) and is being tested in clinical trials 
with and without Peg-IFNα107. Targets against cccDNA include antiviral cytokines (IFNα, IFNγ, TNFα, 
lymphotoxin-β receptor agonists)108 and technologies such as CRISP-R/Cas9 are being utilised to 
eliminate cccDNA along with the use of histone deacetylase (HDAC) inhibitors109,110. It will be 
important to establish if these agents are best deployed in combination with NA’s and/or immune 
modulating agents (Figure 2; potential effects of therapies). Secretion Inhibitors, such as nucleic acid 
polymers (NAPs) have shown promise in inhibiting HBsAg release. Clinical trials of molecules REP-
2044 and REP-2139 used as monotherapy or in combination with Peg-IFNα induced rapid declines of 
HBsAg. In addition, TDF with Peg-IFNα in combination with REP-2139 and REP-2165 have also 
generated promising results111. The core/HBc/Cp proteins have emerged as promising DAA targets 
[Core Allosteric Modulators (CpAM)]. These agents allow for inhibition of nucleocapsid assembly 
leading to the inability of pgRNA enscapsidation or capsid formation with arrest of the neo-synthesis 
of viral rcDNA.112 Whether these will show increased potency in combination with current NAs 
and/or Peg-IFNα remains to be seen. Silencing RNA using RNA interference (RNAi) to prevent HBV 
replication is also being investigated. Preliminary results of a phase II trial showed that a single dose 
of ARC-520 in combination with ETV resulted in rapid decreases in HBV DNA in HBeAg positive and 
negative patients, but only showed a decline in HBsAg in HBeAg positive patients113. It will also be 
interesting to see if viral targets also induce beneficial effects on the host immune response as has 
been shown with DAAs in HCV 114 
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Immune Targets 
Immune therapies include molecules directing innate responses within HBV infected hepatocytes 
triggering antiviral mechanisms (cytokine production, direct killing) of liver non-parenchymal cells. 
Check-point modulators, therapeutic vaccines and targeted T cell therapies are also being 
investigated.  
 
Agents for immune stimulation include pathogen recognition receptor (PRR) agonists, the TLR-7 
agonist GS-9620, which was shown to induce strong anti-HBV activity115, but a trial in CHB patients 
did not show any effect on viral replication/HBsAg levels. However, GS-9620 used as add-on therapy 
in patients virally suppressed with NAs demonstrated increased levels of T-cell effector cytokines 
compared to NAs alone. NK cell activation and function increased after the addition of GS-9620, 
which signalled via the IFN-type I pathway, while the ability of NK cells to delete T cells was 
diminished, indicating the importance of type-I IFN signalling116. The use of TLR-8 and TLR-9 agonists 
may provide more promise, potentially in combination with NAs. Other potential targets for immune 
stimulation include TLR-1/2, RIG-I and stimulator of interferon genes (STING)117. These agents induce 
direct HBV inhibition in infected hepatocytes and SB9200, an oral molecule activating RIG-I is able to 
decrease HBV DNA and HBsAg levels in the WHV, with early clinical trials showing promise in 
humans118. Innate immune therapies have been designed which activate intrahepatic NK/NK-T cell 
responses, with antibody-blocking inhibitory NK cell receptors119 or via NK cell triggering cytokines 
such as IL-12, IL-18120 or with classical IFNα, utilised alone or conjugated with antibodies for selective 
delivery121. Modulation of innate-adaptive interactions could also hold therapeutic promise, for 
example targeting the regulatory role of NK cells and MDSC’s to improve HBV-specific T cell 
immunity82,86. Cytokines such as TNF-α, IL-2 and IL-12 have been shown to inhibit HBV replication in 
vitro and thus could potentially be used with NAs122 However, these molecules have not yet been 
successfully used in clinical trials103. 
 
HBV-specific T cells are exhausted, overexpressing inhibitory check-point molecules such as PD-1 and 
CTLA-4123-125. Blockade of these molecules has shown potential in vitro, with promising data 
emerging in HBV-related HCC with the anti-PD1 agent, Nivolumab126. Anti-PD1/PDL-1 blockade can 
partially restore exhausted HBV-specific T cells in CHB patients125,127 and it will be important to 
determine if these agents are more efficacious in combination with NAs. Therapeutic vaccines, such 
as GS-4774 and TG-1050 are being investigated in clinical trials128,129. These have been designed to 
boost quantity and function of antiviral T cells through HBV-specific stimulation130. Initial trials of 
vaccines showed suboptimal results131,132, but new formulations or combination therapies with NAs 
have demonstrated some effect in selected trials133. Increasing the number of HBV-specific T cells by 
autologous infusion of T cells expressing chimeric antigen receptors (CARs) or by engineering T cells 
to over express HLA-restricted HBV-specific TCRs have been used in human studies and show some 
promise134,135. Design and expansion of engineered HBV-specific T cells for adoptive transfer is 
feasible136,137 and data in animal models138 or selected clinical situations135 have been encouraging, 
but further investigation is required and how best to employ these options in patients remains to be 
seen.   
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Summary 
In order to achieve functional cure in HBV, suppression of HBV replication and a robust host immune 
response are paramount. Many strategies are currently being exploited both as viral and immune 
targets. How best to employ these therapies, whether they should  be used in isolation or in 
combination with currently licensed therapies remains to be seen. NAs and Peg-IFNα used either in 
combination, sequentially or as ‘add-on’ therapies have shown encouraging results in terms of 
clinical outcome along with changes in viral immune responses. However, these studies are limited 
in number, thus comprehensive analyses of the innate and adaptive immune responses along with 
viral parameters, performed in parallel with large clinical trials are mandated to better understand 
clinical outcomes of combination strategies. These results will be critical in determining how best to 
employ novel therapeutics and whether these novel agents should be used in combination with 
currently licensed therapies to maximise treatment response  in a broad range of patients. 
 
Figure Legends 
Figure 1: Timeline indicating the licensing and development of therapies for CHB as indicated by 
national and international guidelines. 
 
Figure 2: Diagram depicting the viral and immune responses with NA and Peg-IFN based therapies, 
and potential viral and immune outcome with novel therapies indicated (used in isolation or in 
combinations) with a view to achieving functional cure in HBV. 
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